Blake Matherne, MD
Ophthalmology · Ocean Springs, MSNPI 1265933626
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 27.2% of the total. 2025 is the largest year on record at $1,156, 5.8 times the $199 reported in 2019.
Across 104 payments — averaging $43.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson Surgical Vision, Inc.$838
- Alcon$674
- Sight Sciences, Inc.$496
- Glaukos Corporation$409
- Rayner Intraocular Lenses Limited$256
- plus $653 from 9 others
What the payments were for
- Food & beverage$4,32895%
- Education$1002%
- Other$1403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $1,242 |
| Johnson & Johnson Surgical Vision, Inc. | 21 | $838 |
| Alcon | 12 | $674 |
| Sight Sciences, Inc. | 15 | $496 |
| Glaukos Corporation | 4 | $409 |
| Rayner Intraocular Lenses Limited | 10 | $256 |
| Ocular Therapeutix, Inc. | 4 | $165 |
| Oyster Point Pharma, Inc. | 4 | $118 |
| Bausch & Lomb Americas Inc. | 1 | $112 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $99 |
| Dompe US, Inc. | 2 | $64 |
| Harrow Eye, LLC | 1 | $37 |
| Biotissue Holdings Inc. | 1 | $21 |
| Amgen | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,568 in reported general payments places this provider in the 75th percentile of 150 ophthalmology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 36 | $23,531 |
| LumiganBimatoprost | 65 | $18,260 |
| XiidraLifitegrast | 12 | $8,221 |
| Prednisolone Acetate | 174 | $5,827 |
| Cyclosporine | 16 | $4,517 |
| Ketorolac Tromethamine | 69 | $3,057 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $2,892 |
| Latanoprost | 305 | $2,452 |
| MoxifloxacinMoxifloxacin Hcl | 86 | $1,947 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 105 | $1,631 |
| Travoprost | 15 | $1,066 |
| Acetazolamide | 227 | $985 |
| ValacyclovirValacyclovir Hcl | 19 | $635 |
| Brimonidine Tartrate | 31 | $474 |
| ErythromycinErythromycin Base | 46 | $473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,242 | $44,684116 claims |
| Bausch & Lomb Americas Inc.Xiidra | $112 | $8,22112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 150 ophthalmology providers in Mississippi.
Other ophthalmology in Ocean Springs
- George ThurberOcean Springs$8K
- Larry FerdinandOcean Springs$4K
- Debra LapradOcean Springs$4K
- James SuttonOcean Springs$3K
- Kiper NelsonHattiesburg$234K
- John ParkerTupelo$72K
- Joseph ChildsTupelo$42K
- Heather HancockJackson$39K
- Leslie AdenFlowood$38K
- Adam QuinnHattiesburg$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.